Kisspeptin-10 vs Prostamax
A side-by-side research comparison of Kisspeptin-10 and Prostamax across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Kisspeptin-10 | Prostamax |
|---|---|---|
| Full name | Kisspeptin-10 (Metastin 45-54) | Prostamax (Prostate Peptide Bioregulator) |
| Category | Sexual Health | Sexual Health |
| Status | Research compound | Research compound (peptide bioregulator) |
| Mechanism | Binds KISS1R on GnRH neurons, stimulating GnRH pulsatile release for LH/FSH secretion. Also enhances limbic sexual arousal circuits. | As a signal peptide, it is proposed to regulate gene expression in prostate tissue, supporting normal prostatic function, reducing inflammation-related dysfunction, and maintaining healthy urogenital tissue. |
| Molecular weight | 1,302 Da | ~ (short peptide) |
| Half-life | 4-6 min (IV) / 20-30 min (SubQ) | Short (peptide) |
| Bioavailability | High (IV/SubQ) | Oral (encapsulated) or subcutaneous |
| Typical dose | 1-10 nmol/kg | ~1-2 capsules/day or short injectable courses |
| Frequency | Single dose or daily | Once daily |
| Route | IV or Subcutaneous | Oral capsule or subcutaneous |
Kisspeptin-10 reported benefits
- Stimulates GnRH naturally
- Increases LH and testosterone
- Enhances sexual arousal (fMRI data)
- Potential fertility aid
- HPG axis diagnostic tool
Prostamax reported benefits
- Prostate tissue support (proposed)
- Male urogenital health
- Anti-inflammatory tissue signaling (proposed)
- Short course-based protocol
Related comparisons
Research and educational reference only. Not medical advice.